Bortezomib shows promise in patients with previously untreated multiple myeloma

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2004年 / 18卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1438 / +
页数：2
相关论文
共 50 条
  • [21] Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma
    Ogawa, Yoshiaki
    Suzuki, Kenshi
    Sakai, Akira
    Iida, Shinsuke
    Ogura, Michinori
    Tobinai, Kensei
    Matsumoto, Morio
    Matsue, Kosei
    Terui, Yasuhito
    Ohashi, Kazuteru
    Ishii, Masami
    Mukai, Harumi Y.
    Ando, Kiyoshi
    Hotta, Tomomitsu
    CANCER SCIENCE, 2013, 104 (07) : 912 - 919
  • [22] Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure
    Malani, Ashok Kumar
    Gupta, Vicram
    Rangineni, Raj
    ACTA HAEMATOLOGICA, 2006, 116 (04) : 255 - 258
  • [23] BORTEZOMIB IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN AND THALIDOMIDE (VDT) FOR THE TREATMENT OF PREVIOUSLY UNTREATED MULTIPLE MYELOMA
    Ailawadhi, S.
    Miller, K. C.
    Depaolo, D.
    Whitworth, A.
    Yu, J.
    Trump, D. L.
    Padmanabhan, S.
    Czuczman, M.
    Bernstein, Z. P.
    Hernandez-Ilizaliturri, F.
    Lee, K.
    Chanan-Khan, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 83 - 83
  • [24] Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide (VDT) for the treatment of previously untreated multiple myeloma
    Chanan-Khan, Asher A.
    Miller, Kena C.
    DePaolo, Dawn
    Padmanabhan, Swaminathan
    Whitworth, Amy
    Ailawadhi, Sikander
    Lee, Kelvin
    Czuczman, Myron S.
    BLOOD, 2007, 110 (11) : 1057A - 1058A
  • [25] PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma.
    Cavenagh, JD
    Popat, R
    Curry, N
    Stec, J
    Morris, TC
    Drake, M
    Agrawal, S
    Smith, P
    Schenkein, DP
    Esseltine, DL
    Oakervee, H
    BLOOD, 2004, 104 (11) : 413A - 413A
  • [26] Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma
    Agustin Avilés
    María J. Nambo
    Natividad Neri
    Claudia Castañeda
    Sergio Cleto
    Judith Huerta-Guzmán
    Medical Oncology, 2007, 24 : 227 - 230
  • [27] Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma
    Aviles, Agustin
    Nambo, Maria J.
    Neri, Natividad
    Castaneda, Claudia
    Cleto, Sergio
    Huerta-Guzman, Judith
    MEDICAL ONCOLOGY, 2007, 24 (02) : 227 - 230
  • [28] Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients
    Buda, Gabriele
    Orciuolo, Enrico
    Carulli, Giovanni
    Galimberti, Sara
    Ghio, Francesco
    Cervetti, Giulia
    Pelosini, Matteo
    Petrini, Mario
    ACTA HAEMATOLOGICA, 2013, 129 (01) : 35 - 39
  • [29] A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients
    Berenson, James R.
    Yellin, Ori
    Chen, Chien-Shing
    Patel, Ravi
    Bessudo, Alberto
    Boccia, Ralph V.
    Yang, Hank H.
    Vescio, Robert
    Yung, Elizabeth
    Mapes, Russell
    Eades, Benjamin
    Hilger, James D.
    Wirtschafter, Eric
    Hilger, Jacqueline
    Nassir, Youram
    Swift, Regina A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (05) : 580 - 587
  • [30] Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up
    Ludwig, Heinz
    Greil, Richard
    Masszi, Tamas
    Spicka, Ivan
    Shpilberg, Ofer
    Hajek, Roman
    Dmoszynska, Anna
    Paiva, Bruno
    Vidriales, Maria-Belen
    Esteves, Graca
    Stoppa, Anne
    Robinson, Don Jr
    Chaturvedi, Shalini
    Ataman, Ozlem
    Enny, Christopher
    Feng, Huaibao
    van de Velde, Helgi
    Viterbo, Luisa
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (03) : 344 - 354
12345